These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

287 related articles for article (PubMed ID: 31112398)

  • 41. Value of early evaluation of treatment response using
    Chen YH; Chang KP; Chu SC; Yen TC; Wang LY; Chang JT; Hsu CL; Ng SH; Liu SH; Chan SC
    Eur J Nucl Med Mol Imaging; 2019 Mar; 46(3):650-660. PubMed ID: 30264225
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Management of Nasopharyngeal Carcinoma: Is Adjuvant Therapy Needed?
    Lee VH; Lam KO; Chang AT; Lam TC; Chiang CL; So TH; Choi CW; Lee AW
    J Oncol Pract; 2018 Oct; 14(10):594-602. PubMed ID: 30312564
    [TBL] [Abstract][Full Text] [Related]  

  • 43. The emerging data on choice of optimal therapy for locally advanced nasopharyngeal carcinoma.
    Hui EP; Ma BBY; Chan ATC
    Curr Opin Oncol; 2020 May; 32(3):187-195. PubMed ID: 32175925
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Meta-analysis of concurrent chemoradiotherapy in the treatment of locoregionally advanced nasopharyngeal carcinoma.
    Wang Y; Ding W; Chen C; Niu Z; Pan M; Zhang H
    J Cancer Res Ther; 2015 Oct; 11 Suppl 2():C191-5. PubMed ID: 26506874
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Proposed modifications and incorporation of plasma Epstein-Barr virus DNA improve the TNM staging system for Epstein-Barr virus-related nasopharyngeal carcinoma.
    Guo R; Tang LL; Mao YP; Du XJ; Chen L; Zhang ZC; Liu LZ; Tian L; Luo XT; Xie YB; Ren J; Sun Y; Ma J
    Cancer; 2019 Jan; 125(1):79-89. PubMed ID: 30351466
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Proton therapy following induction chemotherapy for pediatric and adolescent nasopharyngeal carcinoma.
    Uezono H; Indelicato DJ; Rotondo RL; Sandler ES; Katzenstein HM; Dagan R; Mendenhall WM; Mailhot Vega R; Brennan BM; Bradley JA
    Pediatr Blood Cancer; 2019 Dec; 66(12):e27990. PubMed ID: 31524334
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Chemotherapy in locoregionally advanced nasopharyngeal carcinoma-a review.
    Krstevska V; Stojkovski I
    J BUON; 2008; 13(4):495-503. PubMed ID: 19145670
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Nasopharyngeal carcinoma.
    Chen YP; Chan ATC; Le QT; Blanchard P; Sun Y; Ma J
    Lancet; 2019 Jul; 394(10192):64-80. PubMed ID: 31178151
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Induction chemotherapy plus concurrent chemoradiotherapy versus concurrent chemoradiotherapy alone in locoregionally advanced nasopharyngeal carcinoma: a phase 3, multicentre, randomised controlled trial.
    Sun Y; Li WF; Chen NY; Zhang N; Hu GQ; Xie FY; Sun Y; Chen XZ; Li JG; Zhu XD; Hu CS; Xu XY; Chen YY; Hu WH; Guo L; Mo HY; Chen L; Mao YP; Sun R; Ai P; Liang SB; Long GX; Zheng BM; Feng XL; Gong XC; Li L; Shen CY; Xu JY; Guo Y; Chen YM; Zhang F; Lin L; Tang LL; Liu MZ; Ma J
    Lancet Oncol; 2016 Nov; 17(11):1509-1520. PubMed ID: 27686945
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Phase I trial of nedaplatin chemotherapy concurrent with radiotherapy for untreated locoregionally advanced nasopharyngeal carcinoma.
    Liang Z; Wang S; Lin Z; Feng S; Cheng Z; Yang Y; Kuang Y; Fidelis C; Ullah S; Li F
    Cancer Chemother Pharmacol; 2016 Mar; 77(3):643-51. PubMed ID: 26831498
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Clinical trials in nasopharyngeal carcinoma-past, present and future.
    Xu C; Chen YP; Ma J
    Chin Clin Oncol; 2016 Apr; 5(2):20. PubMed ID: 27121880
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Concurrent chemoradiotherapy in the management of advanced nasopharyngeal carcinoma: current status.
    Afqir S; Ismaili N; Errihani H
    J Cancer Res Ther; 2009; 5(1):3-7. PubMed ID: 19293481
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Predictive value of excision repair cross- complementation group 1 expression in locoregionally advanced nasopharyngeal carcinoma receiving cisplatin-based concurrent chemoradiotherapy.
    Wang D; Zhou J; Zheng J; Zhang J; Chen Y; Li W; Wang R
    Cancer Biomark; 2018; 21(4):875-881. PubMed ID: 29439312
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Concurrent chemoradiotherapy plus adjuvant chemotherapy versus concurrent chemoradiotherapy in locoregionally advanced nasopharyngeal carcinoma : A matched-pair multicenter analysis of outcomes.
    Dong YY; Xiang C; Lu JX; Su YX; Pan YF; Cai R; Zhang RJ; He ZK; Liu ML; Huang H; Bai X; Tang HY; Shi YH; Wang Y; Jiang W
    Strahlenther Onkol; 2016 Jun; 192(6):394-402. PubMed ID: 27215563
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Enhancing efficacy and reducing toxicity: Therapeutic optimization in locoregionally advanced nasopharyngeal carcinoma.
    Jiang W; Lv JW; Tang LL; Sun Y; Chen YP; Ma J
    Cell Rep Med; 2024 Jun; 5(6):101594. PubMed ID: 38843843
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Prospective, Multicenter, Phase 2 Trial of Induction Chemotherapy Followed by Bio-Chemoradiotherapy for Locally Advanced Recurrent Nasopharyngeal Carcinoma.
    Ng WT; Ngan RKC; Kwong DLW; Tung SY; Yuen KT; Kam MKM; Sze HCK; Yiu HHY; Chan LLK; Lung ML; Lee AWM
    Int J Radiat Oncol Biol Phys; 2018 Mar; 100(3):630-638. PubMed ID: 29413277
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Plasma Epstein-Barr viral DNA load at midpoint of radiotherapy course predicts outcome in advanced-stage nasopharyngeal carcinoma.
    Leung SF; Chan KC; Ma BB; Hui EP; Mo F; Chow KC; Leung L; Chu KW; Zee B; Lo YM; Chan AT
    Ann Oncol; 2014 Jun; 25(6):1204-8. PubMed ID: 24638904
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Prognostic value of gross tumor regression and plasma Epstein Barr Virus DNA levels at the end of intensity-modulated radiation therapy in patients with nasopharyngeal carcinoma.
    Liang SB; Zhang N; Chen DM; Yang XL; Chen BH; Zhao H; Lu RL; Chen Y; Fu LW
    Radiother Oncol; 2019 Mar; 132():223-229. PubMed ID: 30366725
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Development and validation of a novel MR imaging predictor of response to induction chemotherapy in locoregionally advanced nasopharyngeal cancer: a randomized controlled trial substudy (NCT01245959).
    Dong D; Zhang F; Zhong LZ; Fang MJ; Huang CL; Yao JJ; Sun Y; Tian J; Ma J; Tang LL
    BMC Med; 2019 Oct; 17(1):190. PubMed ID: 31640711
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Metronomic adjuvant chemotherapy improves treatment outcome in nasopharyngeal carcinoma patients with postradiation persistently detectable plasma Epstein-Barr virus deoxyribonucleic acid.
    Twu CW; Wang WY; Chen CC; Liang KL; Jiang RS; Wu CT; Shih YT; Lin PJ; Liu YC; Lin JC
    Int J Radiat Oncol Biol Phys; 2014 May; 89(1):21-9. PubMed ID: 24725686
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.